ABSTRACT
The world has been suffering from the COVID-19 pandemic since December 2019. One wave after the other has made the situation worse. Conventional treatment protocols and experimental pharmacological interventions have condemned the individuals recovering from active SARS-CoV-2 infection to an iatrogenic immunosuppressive state. The incidence rate of mucormycosis globally varies from 0.005 to 1.7 per million population. In India, the prevalence of mucormycosis is estimated as 140 per million population, which is about 80 times higher than the prevalence in developed countries. Mucormycosis is an angioinvasive, non-contagious but serious life-threatening disease known to be caused by a group of fungi called mucormycetes. The word “mucormycosis” is derived from two Latin words Mucor and mycosis. The group of fungi responsible for mucormycosis tends to enter the body through the respiratory tract, and then depending on the condition, progresses to the other organs of the body.
